Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28223276 | 0.95 | OXER1 (0.53) | OXER1 | |
| SCHEMBL3696937 | 0.93 | OXER1 (0.54) | OXER1 | |
| SCHEMBL7072559 | 0.89 | KMT2A (0.47) | KMT2A | |
| SCHEMBL6942314 | 0.84 | DAO (0.45) | KMT2A | |
| SCHEMBL28047369 | 0.83 | AGTR1 (0.51) | OXER1KMT2AAGTR1AGTR2 | |
| SCHEMBL30005781 | 0.83 | KMT2A (0.46) | KMT2A | |
| SCHEMBL28614887 | 0.81 | KMT2A (0.45) | KMT2A | |
| SCHEMBL1882418 | 0.81 | KMT2A (0.50) | KMT2A | |
| SCHEMBL663 | 0.80 | POLB (0.47) | KMT2A | |
| SCHEMBL7295324 | 0.80 | DAO (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414429-A | Pyrazole compounds and their use as T-type calcium channel blockers | 埃科特莱茵药品有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-100467443-C | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH CORP (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| CN-1543453-A | 6- (aryl-amido or aryl-amidomethyl) -naphthalen-2-yloxy-acid derivatives as plasminogen activator inhibitor type 1 (PAI-1) | — | 2004-11-03 | — | — | CN | disclosed |
| EP-1397341-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | Wyeth (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
| WO-2003000649-A1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | OXER1 656/4885KMT2A 3476/4885AGTR1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.